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1.INTRODUCTION
CHRONIC VENOUS DISEASE 1,2,3,4,5:-
           Chronic venous insufficiency (CVI) is a condition that occurs when the venous wall 
and/or valves in the leg veins are not working effectively, making it difficult for blood to return 
to the heart from the legs. CVI causes blood to “pool” or collect in these veins, and this pooling 
is called stasis.
Causes Chronic Venous Insufficiency:
 Veins return blood to the heart from all the body’s organs. To reach the heart, the blood 
needs to flow upward from the veins in the legs. Calf muscles and the muscles in the feet 
need to contract with each step to squeeze the veins and push the blood upward. To keep 
the blood flowing up, and not back down, the veins contain one-way valves.
 Chronic venous insufficiency occurs when these valves become damaged, allowing the 
blood to leak backward. Valve damage may occur as the result of aging, extended sitting 
or standing or a combination of aging and reduced mobility. When the veins and valves 
are weakened to the point where it is difficult for the blood to flow up to the heart, blood 
pressure in the veins stays elevated for long periods of time, leading to CVI.
 CVI most commonly occurs as the result of a blood clot in the deep veins of the legs, a 
disease known as deep vein thrombosis (DVT). CVI also results from pelvic tumors and 
vascular malformations, and sometimes occurs for unknown reasons. Failure of the 
valves in leg veins to hold blood against gravity leads to sluggish movement of blood 
out of the veins, resulting in swollen legs.
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 Chronic venous insufficiency that develops as a result of DVT is also known as post-
thrombotic syndrome. As many as 30 percent of people with DVT will develop this 
problem within 10 years after diagnosis.
Fig. No.1: Symptoms of Chronic Venous Insufficiency6,7:
 
Symptoms of Chronic Venous Insufficiency8,9,10:
 The seriousness of CVI, along with the complexities of treatment, increase as the disease 
progresses. The problem will not go, and the earlier it is 
diagnosed and treated, the better  chances of preventing serious complications. 
Symptoms include:
 Swelling in the lower legs and ankles, especially after extended periods of standing
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 Aching or tiredness in the legs 
 New varicose veins
 Leathery-looking skin on the legs
 Flaking or itching skin on the legs or feet
 Stasis ulcers (or venous stasis ulcers)
 If CVI is not treated, the pressure and swelling increase until the tiniest blood vessels in 
the legs (capillaries) burst. 
When this happens, the verlying skin takes on a reddish-brown color and is very 
sensitive to being broken if bumped or scratched.
 At the least, burst capillaries can cause local tissue inflammation and internal tissue 
damage. At worst, this leads to ulcers, open sores on the skin surface. These venous 
stasis ulcers can be difficult to heal and can become infected. When the infection is not 
controlled, it can spread to surrounding tissue, a condition known as cellulitis.
 CVI is often associated with varicose veins, which are twisted, enlarged veins close to 
the surface of the skin. They can occur almost anywhere, but most commonly occur in 
the legs.
Risk Factors For Chronic Venous Insufficiency11.12:
 Deep vein thrombosis (DVT)
 Varicose veins or a family history of varicose veins
 Obesity
 Pregnancy
 Inactivity
 Smoking
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 Extended periods of standing or sitting
 Female sex
 Age over 50
CVI Diagnoses13,14:
 To diagnose CVI, a complete medical history and physical examine legs.
 A test called a vascular or duplex ultrasound may be used to examine the blood 
circulation in legs. During the vascular ultrasound, a transducer (small hand-held device) 
is placed on the skin over the vein to be examined. The transducer emits sound waves 
that bounce off the vein. These sound waves are recorded, and an image of the vessel is 
created and displayed on a monitor.
VARICOSE VEINS, VENOUS ULCERS, VARICOSE ULCERS – PROMISING ROLE 
OF CALCIUM DOBESILATE15,16,17,18,19,20:
                Varicose veins and their accompanying secondary complications, namely venous 
ulcers and stasis dermatitis are associated with chronic morbidity, economic loss and reduction in 
the patient’s quality of life. Venous ulcers constitute the majority of leg ulcers, accounting for up 
to 80%8. The overall prevalence of venous ulcers in the general population is in the range of 2%. 
Stasis dermatitis commonly accompanies venous ulcers and is severely disabling to treat.
 Venous ulcers incur substantial costs.
                   Calcium Dobesilate is very effective in the conditions of chronic venous 
insufficiency (CVI), otherwise known as “heavy leg syndrome” or venous varicosities. It acts at 
various levels of the disease process as shown 
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Fig. No.2: Pathogenesis of chronic venous disease:-
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                 Calcium Dobesilate has a comprehensive mode of action. It increases endothelial 
nitric oxide levels by enhancing the activity of nitric oxide synthase and decreasing capillary 
hyper permeability. Calcium Dobesilate shows anti-platelet and fibrinolytic activities by 
inhibiting platelet activation factor (PAF) and enhancing the release of tissue plasminogen 
activator (tPA), thereby improving the local blood flow to tissues, otherwise inhibited due to 
thrombosis. Calcium Dobesilate also inhibits the two pathophysiological reactions in diabetes, 
viz. polyol pathway and glycation of proteins, due to its inhibitory effects on aldose reductase. 
Calcium Dobesilate acts on the endothelial layer and basement membrane of the capillaries. It 
reduces histamine and bradykinin-induced hyperpereability. It increases red blood cell 
membrane flexibility and reduces capillary fragility. Calcium Dobesilate can reduce the platelet 
aggregation stimulated by collagen and thrombin, but not by arachidonic acid. Calcium 
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Dobesilate may also inhibit the formation of sorbitol, thus providing another possible mechanism 
for its usefulness in diabetic retinopathy. Glucose inhibits the formation of both type I and type II 
collagen formation. Calcium Dobesilate does not affect type I inhibition by glucose but 
accelerates type II collagen
                   fibrillogenesis, a major structural component of the arterial wall. Calcium Dobesilate 
has angioprotective action by reducing the permeability and fragility of microvessels, which 
should restrict fluid extravasation into the cardiac interstitium. Itsantiplatelet effect counteracts 
thrombosis and its reduction of plasma viscosity preventsstasis.
Introduction to Targeted Drug Delivery System44,45,46:
                 The goal of any drug delivery system is to provide a therapeutic amount of drug 
to the proper site in the body and then to maintain the desired drug concentration. Conventional 
drug delivery system achieves as well as maintains the drug concentration within the 
therapeutically effective range needed for treatment only when taken several times a day. This 
results in a significant fluctuation in drug level. The concept of designing specified delivery 
system to achieve selective drug targeting has been originated from the perception of Paul 
Ehrlich, who proposed drug delivery to be as a “magic bullet”.
           Controlled and Novel delivery envisages optimized drug in the sense that the therapeutic 
efficacy of a drug is optimized, which also implies nil or minimum side effects. It is expected 
that the 21
st 
century would witness great changes in the area of drug delivery. The products 
may be more potent as well as safer. Target specific dosage delivery is likely to overcome 
much of the criticism of conventional dosage forms. The cumulative outcome could be 
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summarized as optimized drug delivery that encompasses greater potency & greater 
effectiveness, lesser side effects and toxicity, better stability, low cost hence greater 
accessibility, ease of administration and best patient compliance.
 Sustained Release (SR):
            It indicates an initial release of drug sufficient to provide a therapeutic dose soon after 
administration and then a gradual release over an extended period of time. It is substantially 
affected by the external environment. 
Advantages 
฀ Decreased local and systemic side effects.
฀ Better drug utilization.
฀ Improved efficiency in the treatment.
฀ Improved patient compliance.
฀ Increased margin of safety of high potency drugs.
 Disadvantages:
฀ Possibility of dose dumping.
฀ Poor in vitro-in vivo correlation.
฀ Adjustment of dosage regimen is difficult to the physician.
฀ Retrieval of drug is difficult in case of toxicity, poisoning and hypersensitivity.
 Prolonged Release 33,34:
             Provide the slow release of a drug at a rate, which will provide longer duration of action 
than its single dose in a conventional dosage form.
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Controlled Release (CR):
             Delivers the drug at constant predetermined rate locally (or) systemically for a specified 
period of time and independent of external environment, controlled by the design of the system 
itself.
 INTRODUCTION OF MICROSPHERES63,64:
             There is growing interest in the development of homogenous monolithic drug release 
systems for various routes of administration. One very attractive type of such dosage from is 
micro spheres.
  Flexibility in design and development.
 Attractive in appearance.
 Better, improve the safety and efficiency of bio-active agents.
  Desired release pattern can be engineered.
 WHAT IS A MICROSPHERE?
             “Microspheres are defined as solid spherical particles containing dispersed drug in either 
solution or micro-crystalline form”. “A plastic compound used in some dermal fillers for the 
correction of wrinkles that are filled with a substance and released as the shell disintegrates”, 
“Small, hollow glass spheres used as fillers n epoxy and polyester compounds to reduce density”
 ADVANTAGE OF MICROSPHERE
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 Controlled release delivery Biodegradable microspheres are used to control drug release 
rates thereby decreasing toxic side effects, and eliminating the inconvenience of repeated 
injections.
 Biodegradable microspheres have the advantage over large polymer implants in that they 
do not require surgical procedures for implantation and removal.
 PLGA copolymer is one of the synthetic biodegradable and biocompatible polymers that 
have reproducible and slow-release characteristics in vivo.
Types Of Microspheres :
1.Fluorescent Microspheres
             Fluorescent Microspheres are round spherical particles that emit bright colors when 
illuminated by UV light. Ability to emit intense color under UV (black light) illumination 
provides contrast and visibility of Microspheres relative to background materials. For example, 
fluorescent micro beads are often used as traces to simulate spread of viruses in medical 
research. 
              Fluorescent spheres have a unique ability to appear translucent (clear) and practically 
invisible under ordinary light, and emit intense visible color when energized by ultraviolet (UV) 
light. This effect allows scientists and engineers to design blind tests and controlled experiments 
(e.g. simulate spread of viruses) This unique feature of fluorescent Microspheres has numerous 
applications in biomedical research and process troubleshooting.
2.Glass Microsphere
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              Glass Microspheres are microscopic spheres of glass manufactured for a wide variety of 
uses in research, medicine, consumer goods and various industries. Glass Microspheres are 
usually between 1 to 1000 micrometers in diameter, although the sizes can range from 100 
nanometers to 5 millimeters in diameter. Hollow spheres are used as a light weight filler in 
composite materials such as syntactic foam and concrete. Hollow spheres also have uses ranging 
from storage and slow release of pharmaceuticals and radioactive tracers to research in 
controlled storage and release of hydrogen.
 
3.Paramagnetic Microsphere
          They have the ability to increase in magnetization with an applied magnetic field and lose 
their magnetism when the field is removed. Neither hysteretic nor . This property allows efficient 
washing steps, low background and good reproducibility.One use of paramagnetic Microspheres 
as large as 1mm in diameter to simulate salmon eggs, Scientists are able to place them in a 
natural habitat, observe how they move with the water currents and then use their magnetic 
properties to clean them up. 
Different Form Of Polymeric Microspheres
 Albumin Microspheres:-
           The albumin is a widely distributed natural protein. The particulate or the colloidal form 
of albumin is considered as the potential carrier of drug for either there sites specific localization 
or their local application into anatomical discrete sites. Albumin microspheres loaded with 
anticancer drug such as misogynic-C were found to be more effective than the drug alone. 
Burger et al., 1985 observed that cisplatin- loaded microspheres are 10 times more potent in 
targeting the drug to the patient with hyper vascular liver carcinoma.
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 Gelatin Microspheres:-
           It is a biodegradable polymer obtained from the partial hydrolysis of the collagen derived 
from the skin, connective tissue & bones of animals. The acid treated collagen is called type-A & 
the alkali treated is referred as type B.Gelatin microspheres.
The gelatin microspheres being susceptible for the macrophages recognition can be used as 
carrier for the antigens. The antigens from microspheres are released within the macrophages 
upon their degradation leading to enhanced production of antigen specific antibody.
Material used in the preparation of microspheres :-
1. Synthetic polymer
2. Non –biodegradable.
3. PMMA
4. Acrolein
5. Glycidyl methacrylate
6. Epoxy polymers
 Biodegradable  :-
          Lactides and glycosides and these copolymers Poly-alkyl cyano acrylates, poly-
anhydrides.
 Natural materials:-                                                                                                                                      
฀ Protein
฀ Gelatin
฀ Collagen
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฀ Carbohydrates
฀ Agarose
฀ Carrageenan
฀ Chitosan
฀ Chemically modified carbohydrates
฀  DEAE cellulose
฀ Poly (acryl) dextran
฀ Poly (acryl) starch
Method Of Preparation
Solvent evaporation/ double emulsion technique:
            It is most extensively used method of microencapsulation. A buffered or plain aqueous 
solution of the drug (may contain a viscosity building or stabilizing agents) is added to an 
organic phase consisting of the polymer solution in solvents like dichloromethane (or ethyl 
acetate or chloroform) with vigorous stirring to form the primary water in oil emulsion. This 
emulsion is then added to a large volume of water containing an emulsifier like PVA or PVP to 
form the multiple emulsions (w/o/w). The double emulsion, so formed is then subjected to 
stirring until most of the organic solvent evaporates, leaving solid microspheres. The 
microspheres can then be washed, centrifuged and lyophilized to obtain the free flowing and 
dried microspheres.
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Fig. No.3: Depiction of sphere formation by solvent evaporation 
 Single emulsion technique:
            The micro particulate carriers of natural polymers, i.e. those of proteins and 
carbohydrates are prepared by single emulsion technique. The natural polymers are dissolved or 
dispersed in aqueous medium followed by dispersion in the non-aqueous medium e.g., oil. In the 
second step of preparation, cross linking of the dispersed globule is carried out. The cross linking 
can be achieved either by means of heat or by using chemical cross linkers. The chemical cross-
linking agents used include glutaraldehyde, formaldehyde, etc.
 Polymerization techniques:-
          The polymerization techniques conventionally used for the preparation of the micro 
spheres are mainly classified as
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 Normal polymerization:-
           The two processes are carried out in a liquid phase. Normal polymerization proceeds and 
carried out using different technique as bulk suspension precipitation, emulsion and micelle 
polymerization process. In bulk polymerization, a monomer or a mixture of monomer along with 
the initiator is usually heated to initiate the polymerization and carry out the process. One 
catalyst or the initiator is added to the reaction mixture to facilitate or accelerate the rate of the 
reaction. The polymer so obtained may be molded or fragmented as micro spheres. For loading 
of drug, adsorptive drug loading or adding drug during the process of polymerization may be 
opted. They have the ability to increase in magnetization with an applied magnetic field and lose 
their magnetism when the field is removed. Neither hysteretic nor . This property allows efficient 
washing steps, low background and good reproducibility. One use of paramagnetic Microspheres 
as large as 1mm in diameter to simulate salmon eggs, Scientists are able to place them in a 
natural habitat, observe how they move with the water currents and then use their magnetic 
properties to clean them up.
 Interfacial polymerization:-
          Interfacial polymerization essentially proceeds involving reaction of various monomer at 
the interface between the two immiscible liquid phased to form a film of polymer that essentially 
envelops the dispersed phase. In this technique two reacting monomers are employed, one of 
which is dissolved in the continuous phase while the other being dispersed in the continuous 
phase. The continuous phase is generally aqueous in nature through which the second monomer 
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is emulsified. The monomers present in either phase diffuse rapidly and polymerize rapidly at the 
interface.
Phase separation co-acervation techniques:
          Phase separation method is specially designed for preparing the reservoir type of the 
system i.e. to encapsulate water soluble drugs like peptides and proteins. In this technique the 
polymer is first dissolved in a suitable solvent and then drug is dispersed by making its aqueous 
solution.
Spray drying:
         In this process, the drug may be dissolved or dispersed in the polymer solution and spray 
dried. The quality of spray-dried microspheres can be improved by the addition of plasticizers, 
e.g. citric acid, which promote polymer coalescence on the drug particles and hence promote the 
formation of spherical and smooth surfaced microspheres.
The size of microspheres can control by the rate of spraying, the feed rate of polymer drug 
solution, nozzle size, and drying temperature. This method of microencapsulation is particularly 
less dependent on the solubility characteristics of the drug and polymer and is simple, 
reproducible and easy to scale up.
 Solvent extraction:
            This method involves removal of the organic phase by extraction of the organic solvent. 
The method involves water miscible organic solvents such as isopropanol. Organic phase is 
removed by extraction with water. This process decreases the hardening time for the 
microspheres.
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Route of Administration:-
            Micro spheres can be used for the delivery of drugs via different routes. Route of 
administration is selected depending on the drug properties, disease state being treated and the 
condition of the patient. Desirable properties of the microspheres used for the delivery will also 
change depending on the route of administration.
 Oral Delivery:- 
           Oral delivery is the simplest way of drug administration. In oral drug delivery, the 
microspheres have to pass through frequently changing environments in the GI tract. There is 
also patent variation in GI content, so much emptying time and peristaltic activity. Although 
constrains of the oral route are numbers, on the whole, it less potential danger than the pretrial 
route.
            The relatively brief transit time of about 12 h through the GI tract limits the duration of 
action that can be expected via the oral route. Recently, it has been reported that microspheres of 
less than 10 un in size are taken up by the payer’s patches and may increase the retention time in 
the stomach. Eldrige el al. (1990) found that oral administration of poly-lactide co-glycodine 
microspheres containing staphylococcal enter toxin B is effective in including disseminated 
muccal Iga antibody response.
 Parentral delivery:-
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                Most of the micro spheres based controlled delivery system are developed was the aim 
of using them for parental administration. Drug released is completely absorbed in this case. 
Micro spheres used for parental delivery should be sterile and should be dispersible in a suitable 
vehicle for injection hydrophilic micro spheres have the potential advantage of aqueous 
dispensability surfactants in small concentrations are often necessary for reconstituting 
hydrophobic particles for injection is aqueous vehicles which are reported to case adverse tissue 
reactions and affect the incorporated drug. 
Mechanism of drug release:-
             Theoretically, the release of drug from biodegradable micro spheres can he classified 
into four different categories. But actual, the mechanism is more complex and interplay of 
different mechanism may operate.
 Application of Microspheres
 For biodegradable: -
Degradation controlled monolith system:-In degradation controlled monolithic microspheres 
system, the drug is dissolved in the matrix is in degradation controlled monolithic microspheres 
system, the dissolved and is released only on degradation of the matrix. The diffusion of the drug 
is slow compared with the degradation of the matrix. When degradation as by homogeneous bulk 
mechanism, drug release is show initially and increase rapidly when repaid bulk degradation 
starts. Drug release from such type of device in independent of the geometry of the device if the 
degradation is by homogeneous mechanism, degradation is confined to the surface. Hence rate of 
release is affected by the geometry of the device.
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Diffusion controlled monolith system:-
                Here the active is released by diffusion prior to or concurrent with the degradation of 
the polymer matrix. Degeneration of the polymer matrix affects the rate of release and to be 
taken into account. Rate of release also depends on whether the polymer degrades by 
homogeneous or heterogeneous mechanism.
 Erodable polyagent system:-
             In this case the active agent is chemically attach to matrix & the rate of biodegradation 
of matrix is slow compared to the rate of hydrolysis of drug-polymer bond. Assuming that the 
rate of diffusion of active agent from the matrix to the surrounding is rapid, the rate limiting step 
is the rate of cleavage of bond attaching drug to polymer matrix. This type of delivery is obtained 
in the release of norethindrone-17-chlorofirmate which is then attached to the –OH group of 
polymer. In vitro studies in rats using labeled drug polymer conjugate showed that a fairly 
constant release is obtained during the time of observation which was 5 months
 
Utilization of Microspheres in Body:-
            Microparticulate carrier system can be administered through different routes such as i.v, 
ocular, i.m, oral, intra arterial .etc. Each routes has it’s own biological significance, limitation & 
pharmaceutical feasibility. The micro particles are intended to be administration through 
different routes to achieve desired activity of either sustained action or targeting or both. 
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Through different routes different mechanisms of uptake, transport & fate of trans located 
particles have been proposed. Biodegradable micro particulate carriers are of interest for oral 
delivery of drugs to improve bioavailability, to enhance drug absorption, to target particular 
organ 7 to reduce toxicity to improve gastric tolerance of gastric irritant to stomach & as a carrier 
for antigen. The polystyrene microspheres administered orally are reported to be taken up by 
Peyer’s Patch. They are subsequently trans located to discrete anatomical compartments such as 
mecentric lymph vessels, lymph nodes & to a lesser extent in liver & spleen.
 The particulates matters gain entry into follicle associated epithelium through Peyer`s patches. 
After the uptake of particulate carriers via different mechanism their fate become more 
important. Some uptake mechanism avoids the lysosomal system of the enterocytes. The 
particles following uptake by enterocytes are transported to the mecentric lymph, followed by 
systemic circulation & subsecuently phagocyosized by the Kupffer cells of liver. However, after 
uptake by enterocytes, some particulate carriers may be taken up into vacuoles & discharged 
back into gut lumen. Microsperes can also be designed for the controlled release to the 
gastrointestinal tract. The release of drug contents depends on the size of micro particles & the 
drug content within microspheres. The release of the drug could be regulated by selecting an 
appropriate hydrophilic/lipophilic balance of the matrix such as in case of matrix of polyglycerol, 
ester of fatty acids.
             Micro particles of mucoadhesives polymers get attached to the mucous layer in GIT & 
hence, prolong the gastric residence time & functionally offer a sustained release. The 
microspheres of particle size less then 0.87 μm are taken to the general circulation. The fluid 
environment of the GIT can affect the number & rate of particles translocation.
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 In enteric release dosage form.
               Drugs which are irritant to the stomach & other side effects like aspirin, pancrelipase & 
erythromycin, salbutamol sulphate can be incorporated in microspheres for their selective release 
in intestine.
To protect reactive materials against environment.
               It is useful for drugs vitamins. Aspirin which are sensitive to oxygen & water.
To mask bitter of unpleasant taste of the drug.
               E.g. for drugs such as quinidine, nitrofurantion, paracitamol prednisolone, 
metronidazole, fish oils, sulpha drugs, clofibrate, alkaloids & salts.
For drug targeting.
              E.g. casein & gelatin microspheres containing Adriamycin & iterferons respectively 
were magnetically delivered to tumour site. Albumin microspheres used for anti-inflammatory 
agents for directing against knee joints. 
As a topical drug delivery system.
               E.g. Microspheres of benzoyl peroxide for their bactericiday activity against acne.
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As an antidote in the poisoning of heavy metals.
               E.g.  Polymercaptal microspheres as an antidote against mercury poisoning.
As antigen carrier. E.g: PLGA microspheres of varying composition have used to improve the 
ability of the antigens to provoke a mucosal immune response.
To reduce gastric irritation.
             Hard gelatin capsule containing microspheres liberate in stomach & spread in the overall 
GIT, thus ensuring more reproducible drug absorption with less local irritation.8
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2.LITERATURE REVIEW
1. 61Hervt Allain et al, Safety of Calcium Dobesilate in Chronic Venous Disease, Diabetic 
Retinopathy & Haemorrhoids, The aim of the present review is to consider the adverse 
effects and the safety profile of calcium dobesilate. Calcium dobesilate (DoxiumTM)is a 
veno-tonic drug, which is widely prescribed in more than 60 countries. Used chronic 
venous disease , diabetic retinopathy and the symptoms of haemorrhoidal attack. calcium 
dobesilat did not occur very frequently and had the following distributionin terms of 
frequency: fever (26%), gastrointestinal disorders (12.5%), skin reactions (8.2%), 
arthralgia (4.3%), and agranulocytosis (4.3%). No deaths were attributed to calcium 
dobesilate in the PMS report. Most adverse events are type B, i.e. rare and unrelated to 
the phartnacological properties of calcium dobesilate. This review concludes that the rjsk 
of an adverse effect with calcium dobesilate 500-1500 mg/day is low and constant over 
time. The recently raised problem of agranulocytosis (a total of 13 known cases drawn 
from all data sources) appears to be related to methodological bias. Such a review 
reinforces the need for a strong international pharmacovigilance organisation using 
similar methods to detect andanalyse the adverse effects of drugs.
2. (47)Pathak Naresh et al, Formulation & evaluation of floating microspheres of 
Lansoprazole,  the aim of the work is The drug and polymer in different proportions are 
weighed the polymer was co dissolved into previously cooled mixture of Ethanol : 
Dichloromethane at room temperature. The mixture was stir vigorously to form uniform 
drug polymer dispersion. The above organic phase was slowly added to100 ml of distilled 
water & 0.1 HCL containing 0.01% Span 80 by maintain the temperature at 20°C to 30 
°C and emulsified by stirring at 1200 rpm for 30 min . The formed Microspheres were 
filtered & washed with water and sieved between 30-50 mesh size, and dried overnight 
for 40 °C.
3. 62Hiteshkumar D Patel1 et al, Calcium Dobesilate in the symptomatic treatment of 
hemorrhoidal disease: An interventional study: Hemorrhoidal disease is one of the 
commonest ailments that affects mankind and is currently believed to be caused by distal 
displacement and structural distortion of anal cushions, which are physiologic structures 
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randomized, double blind, controlled study was conducted to investigate the efficacy of 
oral and local calcium dobesilate therapy in treating acute attacks of internal hemorrhoids.  
Fiftynine (59)adult patients with first or second-degree internal hemorrhoids were treated 
with calcium dobesilate for six weeks, while 56 patients received only a high fiber diet to 
serve as control. Both symptoms and anoscopic inflammation were scored on a scale from 
0 to 2 before and six weeks after treatment.
4. GD Guptha48  et al:  To prepare and evaluate floating microspheres of silymarin for 
prolonged gastric residence time and increased drug bioavailability.Cellulose 
microspheres – formulated with hydroxylpropyl methylcellulose (HPMC) and 
ethylcellulose (EC) – and Eudragit microspheres – formulated with Eudragit® S 100 (ES) 
and Eudragit® RL (ERL) - were prepared by an emulsion-solvent evaporation method. 
Mean particle size increased while drug release rate decreased with increasing EC and ES 
contents of cellulose and Eudragit microspheres, respectively. The microspheres 
exhibited prolonged drug release for 12 h while still remained buoyant. Drug release 
kinetics, evaluated using the linear regression method, followed Higuchi kinetics and 
drug release mechanism was of the non-Fickian type. The developed floating 
microspheres of silymarin exhibited prolonged drug release in simulated gastric fluid for 
at least 12 h, and, therefore, could potentially improve the bioavailability of the drug as 
well as patient compliance.
5. 2012 Swait49 et al: The purpose of this study was to prepare and characterize 
microspheres loaded by Aceclofenac. To achieve this goal Chitosan and Sodium alginate 
microspheres loaded by Aceclofenac were prepared by emulsification and ionic gelation 
methods. Morphology, size, encapsulation efficiency and drug release from these 
microspheres were evaluated. Microscopic evaluation of microspheres showed that 
microspheres were spherical in shape. The size analysis results indicated that size range 
varied from 1 to 13 μm. Encapsulation efficiency of microspheres was increased by 
increasing drug to polymer ratio. Drug release was found to be Zero order. In conclusion, 
microspheres loaded with Aceclofenac were prepared that could be used for control 
delivery of Aceclofenac.
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6. 2014 Bharat W50 et al: The aim of the present work is to develop the Metoclopramide 
hydrochloride microsphere using Eudragit RL 100 and hydroxyl propyl methyl cellulose 
(HPMC K100) as a polymer by solvent evaporation method for Sustained effect. For the 
preparation of Metoclopramide Hydrochloride Microsphere the solvent system i.e., 
(Dichloromethane and ethanol) and the drug–polymer ratio are use in various 
concentrations, to obtain the desire sustained formulation. Various formulation of 
metoclopramide hydrochloride microsphere was formulated by using Eudragit RL 100 
and HPMC K100 polymers. The E-6 batch microsphere prepared from the Eudragit 
RL100 polymer in that the drug-polymer ratio is 01:1.5, and 01:01 Solvent system (DCM: 
Ethanol), using 2% span 80 as dispersing agent. Metoclopramide hydrochloride 
microsphere E-6 formulation releases the maximum drug i.e., 95.87 ± 0.70 for 12 hrs. The 
kinetic study was carried out and the best fitted kinetic model for E6 optimised batch was 
Korsmeyer peppas have R value 0.998 and k value was 13.62.
7. 2010 Ghodaka51 et al: The present study involves preparation and evaluation of floating 
microspheres with Metformin Hydrochloride as model drug for prolongation of gastric 
residence time. The microspheres were prepared by the emulsification solvent diffusion 
technique using polymers Hydroxypropyl methyl cellulose K4M and Eudragit RS100.. In 
vitro drug release studies were performed and drug release kinetics was evaluated using 
the linear regression method. Effects of the stirring rate during preparation, polymer 
concentration, solvent composition and dissolution medium on the size of microspheres 
and drug release were also observed. The prepared microspheres exhibited prolonged 
drug release (8 h). The mean particle size increased and the drug release rate decreased at 
higher polymer concentration. No significant effect of the stirring rate during preparation 
on drug release was observed. In most cases good in vitro floating behavior was observed 
and a broad variety of drug release pattern could be achieved by variation of the polymer 
and solvent ratio, which was optimized to match target release profile. 
8. 2010 Alireza Mahboubian52 et al: Prepared And Evaluated The   Controlled Release 
PLGA Microparticles Containing Triptorelin. The present study describes the formulation 
of a sustained release microparticulate drug delivery system containing triptoreline 
acetate, using poly (D,L lactide-co-glycolide) (PLGA). Biodegradable microspheres were 
prepared using 50:50 PLGA by a water in-oil-in-water (w/o/w) double emulsion-solvent 
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evaporation procedure. Effect of critical process parameters and formulation variables; 
i.e. volume of inner water phase, addition of NaCl to the outer aqueous phase (W2), 
addition of different types and amounts of emulsifying agents on microsphere 
characteristics; were investigated. Microspheres prepared were spherical with a smooth 
surface, but addition of poloxamer to the first emulsion produced microspheres with large 
pores.  Increasing the inner water phase volume resulted in larger particles with lower 
encapsulation efficiency. Low concentrations of Span 20 decreased triptoreline release 
rate, whereas the addition of poloxamer or high concentrations of Span 20 increased the 
drug release rate. In conclusion, by selecting an appropriate level of the investigated 
parameters, spherical microparticles with encapsulation efficiencies higher than 90% and 
a prolonged triptoreline release over 45 days were obtained.
9. 2006 Ana Rita C.53  et al: prepared controlled release microspheres using supercritical 
ﬂuid technology for delivery of anti-inﬂammatory drugs. Ethylcellulose/methylcellulose 
blends were produced using different precipitation techniques and impregnated with 
naproxen, a non-steroidal anti-inflammatory drug (NSAID). Solvent-evaporation 
technique was used not only for the preparation of ethylcellulose/methylcellulose 
microspheres but also to encapsulate naproxen. Supercritical fluid (SCF) impregnation 
was also performed to prepare naproxen loaded microspheres. In vitro release profiles at 
pH 7.4 and 1.2, of naproxen-loaded microspheres were evaluated and the results were 
modelled Fick's law of diffusion and Power law. Miscrospheres prepared by supercritical 
antisolvent have a higher loading capacity and present a slower release profile. The 
systems studied present a release mechanism controlled by drug diffusion which complies 
Fick's law of diffusion.
10. 2010 B.Appa Rao et al: Reported prolonged-release microcapsules of diclofenac sodium 
(DS) were prepared by employing ethyl cellulose as a polymer in various ratios of 1:1, 
2:3 & 2:1, by emulsion solvent evaporation technique. Scanning electron microscope 
photographs of samples revealed that all prepared microcapsules were almost spherical in 
shape and have a slightly smooth surface. The encapsulation efficiency was found to be in 
the range of 66.17 -72.99%. The In-vitro release profile of diclofenac indicates that all the 
batches of microcapsules showed controlled and prolonged drug release over an extended 
period of 10 h. The release kinetics study reveals that the drug follows first order kinetics 
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and the mechanism of drug release was diffusion controlled type. The author concluded 
that Sustained release DS microcapsules could be formulated by using ethyl cellulose as a 
release retardant by emulsion solvent evaporation technique. Increasing the polymer 
concentration in microcapsule formulation decreases the rate of drug release dramatically.
11. 2000 J.M. Teijon55  et al: studied the Chitosan microspheres in PLG films as devices for 
cytarabine release. Cytarabine was included in chitosan microspheres and several of these 
microspheres were embedded in a poly (lactide-co-glycolide) (PLG) film to constitute a 
comatrix system, to develop a prolonged release form. Chitosan microspheres, in the 
range of 92±65 μm, having good spherical geometry and a smooth surface incorporating 
cytarabine, were prepared. The cytarabine amount included in chitosan microspheres was 
43.7μg of ara-C per milligram microsphere. The incorporation efficiency of the 
cytarabine in microspheres was 70.6%. Total cytarabine release from microspheres In-
vitro was detected at 48h. Inclusion of cytarabine-loaded microspheres in poly (lactide-
co-glycolide) film initiated a slower release of the drug and, in this way, the maximum of 
cytarabine released (80%) took place in vitro at 94.5 h.  
12. 2005 Sinha VR56  et al:  formulated and characterized the Ketorolac tromethamine 
biodegradable microspheres. Ketorolac tromethamine has to be given every 6 hr 
intramuscularly in patients for acute pain, so to avoid frequent dosing and patient 
inconvenience we found it to be a suitable candidate for parenteral controlled delivery by 
biodegradable microspheres for the present study. Ketorolac tromethamine-loaded 
microspheres were prepared by o/w emulsion solvent evaporation technique using 
different polymers: polycaprolactone, poly lactic-co-glycolic acid (PLGA 65/35), and 
poly lactic-co-glycolic acid (PLGA 85/15). In pure PLGA65/35 and PLGA85/15, particle 
size was 28 micron and 8 micron, respectively. Surface topography was studied by 
scanning electron microscopy that revealed a spherical shape of microspheres. From our 
study it as concluded that with careful selection of different polymers and their 
combinations, we can tailor the release of ketorolac tromethamine for long periods.
13.  2008 Xia CHEN57   et al: Prepared and characterized biodegradable Polylactide (PLA) 
Microspheres Encapsulating Ginsenoside Rg3. The microspheres surface was smooth. 
Particle size analysis results showed that the diameters of the microspheres encapsulating 
ginsenoside Rg3 were even larger than those of the non encapsulated ones and they were 
rather homogeneous in size. For in vitro drug release experiments, the dialysis dynamic 
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method was applied. Among the experimental methods available for determining the in 
vitro release profiles from colloidal suspension, this method was the most suitable, to 
release the drugs rapidly and completely in the releasing medium. Ginsenoside Rg3 PLA 
microspheres were prepared by using the emulsion solvent evaporation method. The 
controlled release of ginsenoside Rg3 from PLA microspheres could be explained by a 
diffusion mechanism, which was in good agreement with the Heller-Baker Model.
14. 2012 Yagnesh Bhatt58  et al: reported influence of additives on fabrication and release 
from protein loaded PLGA microparticles. The encapsulation efficiency was reduced by 
adding PEG 1450 into oil phase during the emulsification. The Encapsulation efficiencies 
of BSA within microparticles were 43% ± 0.63, 36% ± 0.85, 52% ± 1.02 for PLGA/PEG 
ratios 1:1, 1:2 and 2:1 respectively, where PLGA microparticles without PEG 1450 
shown slightly higher encapsulation efficiencies (56% ± 0.23). The control microparticles 
showed a smooth, nonporous surface while the microparticles with PEG exhibited a 
highly porous surface. These studies have shown that the incorporation of additives PEG 
1450 significantly increased the early-stage release of BSA from PLGA microparticles in 
comparison to the control. There was no improvement in encapsulation efficiency. In the 
case of surfactants, PVA was found to be the most efficient surfactant in very less 
concentration (0.25–0.5 % w/v) considering both the encapsulation efficiency and the size 
reducing effect in comparison of polaxomer 407.
15. 2003 Yilmaz Capan59 et al: assessed the physicochemical properties of a controlled 
release formulation of recombinant human growth hormone (rHGH) encapsulated in poly 
(D,L-lactide-co-glycolide) (PLGA) composite microspheres. rHGH was loaded in 
poly(acryloyl hydroxyethyl) starch (acHES) microparticles, and then the protein-
containing microparticles were encapsulated in the PLGA matrix by a solvent 
extraction/evaporation method. rHGH-loaded PLGA microspheres were also prepared 
using mannitol without the starch hydrogel microparticle microspheres for comparison. 
The composite microspheres were spherical in shape (44.6±2.47 μm), and the PLGA-
mannitol microspheres were 39.7±2.50 μm. Drug-loading efficiency varied from 93.2% 
to 104%. The composite microspheres showed higher overall drug release than the 
PLGA/mannitol microspheres. FTIR analyses indicated good stability and structural 
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integrity of HGH localized in the microspheres. The PLGA-acHES composite 
microsphere system could be useful for the controlled delivery of protein drugs.
16. 2004 Y. Yeo60 et al: studied the control of encapsulation efficiency and initial burst in 
polymeric microparticle systems. Initial burst is one of the major challenges in protein-
encapsulated microparticle systems. Since protein release during the initial stage depends 
mostly on the diffusional escape of the protein, major approaches to prevent the initial 
burst have focused on efficient encapsulation of the protein within the microparticles. For 
this reason, control of encapsulation efficiency and the extent of initial burst are based on 
common formulation parameters. The present article provides a literature review of the 
formulation parameters that are known to influence the two properties in the emulsion-
solvent evaporation/extraction method. Physical and chemical properties of encapsulating 
polymers, solvent systems, polymer-drug interactions, and properties of the continuous 
phase are some of the influential variables. Most parameters affect encapsulation 
efficiency and initial burst by modifying solidification rate of the dispersed phase. In 
order to prevent many unfavorable events such as pore formation, drug loss, and drug 
migration that occur while the dispersed phase is in the semi-solid state, it is important to 
understand and optimize these variables.
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3.AIM AND OBJECTIVE
AIM OF PRESENT STUDY:
 Calcium Dobesilate is   controlled release microspheres are gaining prominence as new 
targeted drug delivery system. This dosage form has to be administered orally for controlling 
the drug release. In this study, an effort has been made to formulate controlled release 
microspheres using polymer HPMC K100, Ethyl Cellulose, Eudragit L100, Sodium Alginate. 
Controlled release microspheres are gaining prominence as new targeted drug delivery 
system. In this study we aim to formulation and evaluation of Calcium Dobesilate 
microspheres for the treatment of chronic venous disease.
             Hence The  Calcium Dobesilate as design controlled release microspheres provided  
following benefits
1. Microspheres in improve treatment efficacy while reducing toxicity.
2. The microspheres continue to protect the encauplasting agent after administration.
3. site specific drug can be achieved.
4.  The microspheres release encapsulation molecules over extended time intervals up to   
24 hrs.
5. drug is having Short half life, high water solubility to prolong the pharmacological 
action  ideal candidate for design of controlled release microspheres formulation.
6. Constant drug releases for better therapeutic action.
7. In order to improve patient compliance . 
8. Maintain therapeutic window, obtain controlled Drug release.
9. To reduce cost effect
10. To reduce side effects.
11. To reduce dosage frequency.
12. Long duration of action.
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OBJECTIVE OF PRESENT STUDY 
      Following objectives to develop to the formulation development and evaluation of 
Calcium Dobesilate microspheres.
฀ To perform pre formulation studies.
฀ To prepare the microspheres by using different methods- Ionic Gelation, Emulsion 
Solvent Evaporation method, Emulsification Ionic Gelation Method.
฀ Selection of appropriate method for preparation of microspheres.
฀ Study effect of various formulations and process variables on Microspheres size, 
entrapment efficiency and In-vitro release studies.
฀ Evaluate the effect of different independent variables such as polymer concentration, 
Calcium chloride concentration and stirring speed.  
฀ To determine the compatibility of drug with the polymer by FTIR studies.
฀ Study effect of various formulations for In-vitro drug release and release kinetics.
฀ To carry out stability studies of Calcium Dobesilate microspheres.
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4.DRUG AND EXCIPIENT PROFILE
1.CALCIUM DOBESILATE:-
Fig. No.4:Chemical structure of CALCIUM DOBESILATE:-
 Calcium Dobesilate           : Calcium di(2,5-dihydroxybenzenesulphonate) monohydrate
Chemical IUPAC Name    :  Calcium di(2,5-dihydroxybenzenesulphonate) monohydrate                                                                                                    
Trade Name                        : Doxium
Category                             :  Venotonic, 
Chemical Formula            :   C12H10CaO10S2,H2O 
Molecular Weight             :   418.41g/mol
Melting Point                     :  251°C 
Mechanism of Action22,23,24: 
Calcium dobesilate has a comprehensive mode of action. It increases endothelial nitric 
oxide levels by enhancing the activity of nitric oxide synthase and decreasing capillary 
hyperpermeability. Calcium dobesilate shows anti-platelet and fibrinolytic activities by inhibiting 
platelet activation factor (PAF) and enhancing the release of tissue plasminogen activator (tPA), 
thereby improving the local blood flow to tissues, otherwise inhibited due to thrombosis. 
Calcium dobesilate also inhibits the two pathophysiological reactions in diabetes, viz. polyol 
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pathway and glycation of proteins, due to its inhibitory effects on aldose reductase. Calcium 
dobesilate acts on the endothelial layer and basement membrane of the capillaries. It reduces 
histamine and bradykinin-induced hyperpermeability. It increases red blood cell membrane 
flexibility and reduces capillary fragility. Calcium dobesilate can reduce theplatelet aggregation 
stimulated by collagen and thrombin, but not by arachidonic acid.Calcium dobesilate may also 
inhibit the formation of sorbitol, thus providing another possible mechanism for its usefulness in 
diabetic retinopathy.Glucose inhibits the formation of both type I and type II collagen formation. 
Calciumdobesilate does not affect type I inhibition by glucose but accelerates type II collagen 
fibrillogenesis,a major structural component of the arterial wall. Calcium dobesilate 
hasangioprotective action by reducing the permeability and fragility of microvessels, which 
should restrict fluid extravasation into the cardiac interstitium. Itsantiplatelet effect counteracts 
thrombosis and its reduction of plasma viscosity preventastasis.
Physical data24:
Colour    :  White Powder
Odour   :  None
 Taste    :  Bitter
 Solubility : very soluble in water ,freely soluble in Ethanol, Slightly soluble in  2propanol, 
soluble in Methanol , practically insoluble in methylene chloride.
Table No.1:
 Pharmacokinetic data25:
Protein binding 25%
Metabolism Kidney
Half life 2 hours
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Indications:  
Calcium dobesilate is indicated for the treatment of chronic venous disease diabetic 
retinopathy, haemmeriods (piles) 
 Clinical particulars26,27,28:
 Therapeutic indications
             Microangiopathies, in particular diabetic retinopathy. Clinical signs of chronic venous 
insufficiency in the lower limbs (pain, cramps, paresthesia, oedema, stasis dermatosis), as 
adjuvant in superficial thrombophlebitis. Haemorrhoidal syndrome, microcirculation disorders
of arteriovenous origin.
 Posology and method of administration
Generally 500 to 1000 mg – 1 capsule once or twice a day - to be taken with the main 
meals. Treatment duration, which is generally between a few weeks and several months, depends 
on the disease and its evolution. Dosage should be adapted individually according to the severity 
of the case.
Contra-indications
Hypersensitivity towards calcium Dobesilate.
Special warnings and special precautions for use
Dosage should be reduced in case of severe renal insufficiency requiring dialysis.
In very rare cases (0.32/million patients), incidence estimated on the basis of spontaneous 
reports, the intake of calcium dobesilate may induce agranulocytosis, probably linked to a 
hypersensitivity reaction. This condition may be expressed by symptoms such as high fever, oral 
cavity infections (tonsillitis), sore throat, anogenital inflammation and accompanying symptoms, 
that are often signs of an infection. The patient should be told that by any sign of infection he/she 
must immediately inform his/ her physician. In that case, it is essential to control without delay
the blood formula and leucogram and to discontinue the treatment.
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Interactions with other medicinal products and other forms of interaction
No interaction is known up to now.
At therapeutic doses, calcium dobesilate may interfere with creatinine assay by giving lower 
values.
Pregnancy and lactation
Pregnancy category C: studies in pregnant women or animals are not available. As it is 
not known whether calcium dobesilate crosses the placental barrier in humans, the drug should 
only be administered if the potential benefit justifies the potential risk to the foetus. Calcium 
dobesilate enters the maternal milk in very low quantities (0,4 μg/ml after intake of 3x500 mg). 
As a precaution, either the treatment or the breastfeeding should be stopped.
Effects on ability to drive and use machines
          Doxium 500 has no effect upon driving capacity and managing of machines.
Gastrointestinal disorders
Rare : nausea, diarrhoea, vomiting.
Skin and subcutaneous tissue disorders
Rare: pruritus,rash.
General disorders and administration site conditions
Rare: fever,chills.
Musculoskeletal disorders
Rare : arthralgia.
Cardiac disorders
Uncommon: tachycardia.
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Blood and lymphatic system disorders:
Isolated cases of agranulocytosis have been reported mainly in elderly patients and in 
combination with other drugs. These reactions are generally reversible when stopping
treatment course. In case of gastrointestinal disorders, the dosage should be reduced or the 
treatment temporarily withdrawn. In case of skin reactions, fever, articular pain or change in 
blood formula, the treatment must be stopped and the treating physician informed as this may 
constitute hypersensitivity reactions.
Pharmacodynamic properties29,:
Regulator of capillary functions. Calcium dobesilate acts on the capillary walls by 
regulating its impaired physiological functions - increased permeability and decreased resistance. 
It increases erythrocyte flexibility, inhibits platelet hyperaggregation and, in diabetic retinopathy, 
it reduces plasma and blood hyperviscosity, thus improving blood rheological properties and 
tissue irrigation. These effects allow to correct capillarydysfunctions either of functional origin 
or caused by constitutional or acquired metabolic disorders. Calcium dobesilate contributes to 
reduce oedema.
Pharmacokinetic properties30,31:
After oral administration of 500 mg of calcium dobesilate, its blood level is above 6 
μg/ml between the 3rd and 10th hour, with a maximum (Cmax) of 8 μg/ ml on the average after 
6 hours (tmax). Twenty four hours after intake blood level is about 3 μg/ml. The rate of protein-
binding is 20 - 25%. In animals, calcium dobesilate does not cross the haematoencephalic or the 
placental barrier, but it is not known whether this is also the case in humans. Calcium dobesilate 
enters the maternal milk in very low quantities (0,4 μg/ml after intake of 1500 mg as observed in 
one study). Calcium dobesilate does not enter the enterohepatic cycle and is excreted mainly 
unchanged with only 10% being excreted as metabolites. About 50% of the orally administered 
dose are eliminated in the first 24-hour urine and about 50% in the faeces. Plasma half-life is 
around 5 hours. Kinetics in particular clinical situations It is not known to what extent renal 
function disorders influence the pharmacokinetic properties of calcium dobesilate (see 
“Precautions”).
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Preclinical safety data32:
Acute and chronic toxicity studies, foetotoxicity and mutagenicity studies on calcium 
dobesilate have not revealed any toxic effect.
 
2.EUDRAGIT L 100-55 40 :
EUDRAGIT® L 100-55 contains an anionic copolymer based on methacrylic acid and ethyl 
acrylate. It is prepared by Spray drying of Eudragit L 30 D-55
Physical properties:  It is a white free flowing powder 95% dry redispersible in water to form a 
latex ratio of free –COOH groups to ester groups is 1:1. Films dissolve above pH 5.5 forming 
salts with alkalis thus affording coatings which are insoluble in gastric media, but are soluble in 
Small Intestine
Figure. No.5:Chemical structure of EUDRAGIT® L 100-55 40 :
Targeted Drug Release Area:  duodenum 
Dissolution:                        above pH 5.5
Characteristics:
 Effective and stable enteric coatings with a fast dissolution in the upper Bowel
 Granulation of drug substances in powder form for controlled release 
 Site specific drug delivery in intestine by combination with EUDRAGIT® S grades
 Variable release profiles
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Solubility: 1 g of EUDRAGIT
® 
L 100-55 dissolves in 7 g methanol, ethanol, isopropyl alcohol 
and acetone, as well as in 1 N sodium hydroxide to give clear to cloudy solutions. It is practically 
insoluble in ethyl acetate, methylene chloride, petroleum ether and water.
Viscosity / Apparent viscosity: 100 - 200 mPa.s 
Storage: Store at controlled room temperatures (USP, General Notices). Protect against 
moisture. Any storage between 8 °C and 25 °C fulfils this requirement. 
Stability: Minimum stability dates are given on the product labels and batch-related Certificates 
of Analysis. Storage Stability data are available upon request.
3.SODIUM ALGINATE35,36,43:
Figure. No.6:Chemical structure of SODIUM ALGINATE: 
Empirical formula: (C6H7O6Na) n
Synonym: Alginic acid, algin, sodium poly nuronate, Kelcosol, Keltone, Sodium 
polymannuronate.
Description: Sodium alginate (ALG) is the purified carbohydrate product extracted from brown 
sea weed by the use of dilute alkali. It consists chiefly of the sodium salt of alginic acid, a 
polyuronic acid composed of β-D-mannuronic acid residues so that the carboxyl group of each 
unit is free while the aldehyde group is shielded by a glycosidic linkage. Sodium alginate occurs 
as white to pale yellowish brown colour powder which is odourless and tasteless. Sodium 
alginate is practically insoluble in ethanol (95%), ether, chloroform, and ethanol/water   mixtures 
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in   which the ethanol   content   is greater than 30%. Also, practically insoluble in other organic 
solvents and aqueous acidic solutions in which the pH is less than 3, poorly soluble in water, 
forming a viscous colloidal solution. The powder may be coarse and having viscosity of 20-
400cps at 200c (1% aqueous solution) and of 1% w/v aqueous solution is having pH 7.2.
Storage: Sodium alginate is a hygroscopic material. It should be stored at low relative humidity 
and a cool temperature. Numerous studies have indicated sodium alginate to be quite safe allergy 
tests have shown it to be non allergenic.
Incompatibility: It is incompatible with acridine derivatives, crystal violet, phenyl   mercuric 
nitrate and acetate, calcium salts, alcohol in concentrations greater than 5% and heavy metals.
Applications 
฀ Used as stabilizing agent in emulsions, as suspending agent, thickening agent, tablet 
disintegrating agent and tablet binder. 
฀ Used as haemostatic agent in surgical dressings. 
฀ Used for the aqueous microencapsulation of drugs in contrast with the more conventional 
microencapsulation techniques used in combination with an H2 receptors antagonist in the 
management of gastro oesophageal reflex. 
฀ Used in the preparation of sustained release oral formulations, since it can delay the 
dissolution of the drugs from tablet and aqueous suspensions. 
฀ Used in cosmetics and food products. 
฀ Used in the modulation of gastrointestinal transit time and delivery of biomolecules like 
DNA, proteins and cells.14-22
4.HYDROXY PROPYL METHYL CELLULOSE K10037,38,42:
Figure. No.7:Chemical Structure of HYDROXY PROPYL METHYL CELLULOSE:
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Non Proprietary Name:
British pharmacopoeia            : Hypromellose
United State Pharmacopoeia  : Hydroxy Propyl Methyl cellulose
Synonyms :  Methocel, HPMC
Chemical Name                    :  Cellulose, 2-Hydroxypropyl methyl ether methanol
Stability :  Stable in dry condition from pH 3.0 to 11.0
Storage Condition                : It is hygroscopic in nature. Should be stored in well-
closed container, in a cool and dry place.
Incompatibilities :   Incompatible with some oxidizing agents. Since it’s nonionic, 
hydroxy methyl cellulose will not complex   with metallic effect.
Safety :   It’s generally regarded as a nontoxic and non-irritant material 
although excessive oral consumption may have a laxative effect.
Application : HPMC is widely used in oral and topical pharmaceutical 
formulations. In oral products, it primarily used tablet binder.25
5.ETHYL CELLULOSE39,40,41:
Figure. No.8:Chemical structure of ETHYL CELLULOSE:
  
Synonyms: Ethocel 
Nonproprietary Names: BP: Ethylcellulose 
                                                PhEur: Ethylcellulosum 
Chemical Name            : Cellulose ethyl ether 
CAS Registry Number : 9004-57-3 
Empirical Formula: C12H23O6 (C12H22O5)n-2 C12H23O5  
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Functional category: Coating agent; flavoring fixative; tablet binder; tablet filler; viscosity-
increasing agent. 
Description: Ethyl cellulose is a tasteless, free-flowing, white to light tan-colored powder. 
 Solubility: 40Insoluble in water and glycerin, but soluble in certain organic solvents, 
depending upon ethoxy content. 
 Stability and Storage Conditions:It is resistant to alkalis, both dilute and concentrated, and 
to salt solutions. It is more sensitive to acidic materials than are cellulose esters. However, 
the material can withstand dilute acids for a limited period of exposure. Ethyl cellulose is 
subject to oxidative degradation in the presence of sunlight or UV light at elevated 
temperatures. 
 This may be prevented by use of an antioxidant and a compound with light absorption 
properties between 230-340 nm. Ethyl cellulose should be stored between 7° and 32°C in a 
dry area away from all sources of heat. Store in a well-closed container. 
Incompatibilities: Incompatible with paraffin wax and microcrystalline wax. 
Safety: Ethyl cellulose is widely used in oral and topical pharmaceutical formulations. It is 
also used in food products. Ethyl cellulose is generally regarded as a nontoxic, non 
allergenic, and nonirritating material. As ethyl cellulose is not considered to be a health 
hazard, the WHO has not specified an acceptable daily intake. 26
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5.PLAN OF WORK
Plan of Work
฀ Literature survey
฀ Selection of drug
฀ Standard calibration curve of Calcium Dobesilate.
฀ Preparation of Calcium Dobesilate microspheres
฀ Evaluation of  Microspheres
฀ Preformulation studies
 FT-IR studies
฀ Evaluation parameters
 Determination of percentage yield
 Drug entrapment efficiency 
 Particle size analysis
 In-vitro drug release
 In-vitro drug release kinetics
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6.MATERIALS AND METHODS
Materials used in the present research work: 
Table No.2:
S.NO NAME OF THE PRODUCT NAME OF THE SUPPLIER
1 Calcium Dobesilate Qualikems fine chem...pvt, Ltd
2 HPMC K100 Qualikems fine chem...pvt, Ltd
3 Eudragit L100 Otto chemika-biochemica reagent
4 Ethyl Cellulose Suvidhnath Laboratories,Baroda
5 Sodium alginate Finars Reagents,Ahmedabad
6 Ethanol Suvidhnath Laboratories,Baroda
7 Methanol Qualikems fine chem...pvt, Ltd
8 Span 80 Samir tech-chem pvt.Ltd  Vadodara
9 Potassium di hydrogen ortho phosphate Qualikems fine chem...pvt, Ltd
10 Sodium Hydroxide Qualikems fine chem...pvt, Ltd
11 Calcium chloride Indian Research Products IRP
12 Dichloromethane Karnataka fine chemical ,Bangalore
13 Groundnut oil Vk. Pharamavceuticals, Hydrabad
14 HCL Qualikems fine chem...pvt, Ltd
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Equipment used in present work:
Table No.3:
S.NO Name of the Instrument Model and Manufacture/supplier
1 High precision balance    Sartorius-bsa224s-CW, Mombay
2 U.V/Visible spectrophotometer  LAB INDIA
3 Magnetic stirrer LAB INDIA
4  Dissolution test apparatuses LAB INDIA , Navi Mumbai
5 pH meter LAB INDIA, 
6 Melting point apparatuses LAB INDIA, Mumbai
7 Tapped density apparatuses LAB INDIA
8 Glass ware Borosil
 
PREFORMULATION STUDIES:
Preformulation studies are the first step in the rational development of dosage form of drug 
substance. Preformulation can be defined as investigation of physical and chemical properties of 
drug substance alone when combined with excipients.
The following Preformulation studies were performed for Calcium Dobesilate
1. Solubility
2.  Melting point Determination.
3. Density
4. Carr’s Index
5. Hauser’s Ratio
6. Angle of repose
7. FT-IR Spectral studies
8. Stability Studies
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1.Solubility:
The solubility of drug is an important physicochemical property because it affects the 
bioavailability of the drug, the rate of drug release into dissolution medium and consequently, the 
therapeutic efficiency of the pharmaceutical product. The solubility of the molecules in various 
solvents is determined as a first step. Solubility is usually determined in variety of commonly used 
solvents and some oils if the molecules are lipophilic. The solubility of material is usually 
determined by the equilibrium solubility method, which employs a saturated solution of the 
material, obtained by stirring an excess of material in the solvent for a prolonged until equilibrium 
is achieved. A known  quantity  of  solute  was  dispersed  in  the  solvent  and  based  on 
following table the solubility was determined.
A known quantity of solute was dispersed in the solvent and based on following table the 
solubility was determine
Solubility chart
Table No.4:
Descriptive term Approximate volume of solvent in
milliliters per gram of solute
millilitersper gram of soluteVery soluble
Freely soluble
Soluble
Sparingly soluble
Slightly soluble
Very slightly soluble
Practically insoluble
Less than 1
From 1 to 10
From10 to 30
From 30 to 100
From 100 to 1000
From 1000 to 10,000
More than 10,000
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2.Melting Point Determination:
A characteristic of a pure substance is a defined melting point or melting range. If not pure, 
the substance will exhibit a change in melting point. This phenomenon is commonly used to 
determine the purity of a drug substance and in some cases the compatibility of various substances 
before inclusion in the same dosage form. it is determined by capillary tube method.
3.Density:
1.Bulk Density (Db):
It is the ratio of total mass of powder to the bulk volume of powder. It was measured by 
pouring the weighed powder into a measuring cylinder and the volume was noted. It is expressed 
in gm/ml and is given by
Db
Where M = is the mass of powder.
Vb =is the bulk volume of the powder.
2.Tapped Density (Dt):   
Fig. No.9: Tapped Density:
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It is the ratio of total mass of powder to the tapped volume of powder. The tapped volume was 
measured by tapping the powder for 750 times and the tapped volume was noted if difference 
between these two volumes is less than 2%. If it is more than 2%,tapping  is continued for 1250 
times and tapped  volume was noted. Tapping was continued until the difference between 
successive volumes is less than 2% (in a bulk density apparatus).
 It is expressed in gm/ml and is given by
Dt
M= is the mass of powder.
Vt=isthetapped volume of the powder
4.Carr’s Index (I): (or) % compressibility:
It indicates the ease with which a material can be induced to flow. It is expressed in 
percentage and is given by
                               I=[Dt-Db/Dt] X100
Where,
Dt=is the tapped density of the powder. Db=is 
the bulk density of the powder.
 Relationship between % compressibility and Type of flow
Table No.5:
Carr’s index (%)Type of flow
5-12 Excellent
12-18 Good
18-23 Fair to passable
23-35 Poor
35-38 Very Poor
CHAPTETR 6                                                                                                     MATERIALS AND 
METHODS
 Dept. of Pharmaceutics,Annai Veilankanni’s Pharmacy College, Saidapet. Page 47
>40 Extremely Poor
5.Angle of Repose (θ):
Fig. No.10:
The friction forces in a loose powder can be measured by the angle of repose θ. It is 
defined as maximum angle possible between the surface of a pile of powder and the horizontal 
plane.  The powder mixture was allowed to flow through the funnel fixed to a stand at definite 
height (h). The angle  of repose was the calculated by measuring the height and radius of the 
heap of powder formed.
tan θ
θ=tan-1(h/r)
Where, θ is the Angle of repose,
              h is height of pile,
               r is radius of pile,
Table No.6: Angle of Repose as an Indication of Powder Flow Properties I.P standard 
values: 
ANGLEOF REPOSE (In degrees) TYPEOF FLOW
<25 Excellent
25-30 Good
30-40 Passable
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>40 Very Poor
6.Hauser’s ratio:
Hausner ratio is an indirect index of ease of powder flow. It is calculated by the 
following formula
              Hausner’s ratio = Dt/Db
Where, DT is the tapped density.
Db is the bulk volume.
Table No.7: Hausner’s ratio values:
Hausner’sratio Typeof flow
<1.25 Good
                      1.25-1.5 Moderate
> 1.5 Poor
 
7.FT-IR Spectral studies:
The IR spectra for the formulation excipients and pure drugs were recorded on BRUKER FT-
Infrared spectrophotometer using ATR technique at the resolution rate of 2-2.5µm Spectrum was 
integrated in transmittance mode at the wave number range 400-4000 cm-1
Analytical method Development by UV/Visible Spectrophotometer:
Standard calibration with 6.8 pH phosphate buffer
Preparation of Stock solution
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       100 mg of Calcium Dobesilate was solubilized ethanol then dissolved in 100 ml of 6.8 pH 
phosphate buffer in a 100 ml volumetric flask and made up to the volume with 6.8 pH phosphate 
buffer. From this 10 ml of solution was taken and made to 100 ml with 6.8 pH phosphate buffer.
Method
      For the estimation of Calcium Dobesilate in 6.8 pH phosphate buffer the stock solution has to 
be diluted subsequently with 6.8 pH phosphate buffer to get a series of dilutions containing 
10,20,30,40 &50 µg/ml of solution.  The absorbance of these solutions were measured at 302 nm 
against blank.
PREPARATION OF CALCIUM DOBESILATE MICROSPHERES:
1.Orifice Ionic Gelation Method30-31: 
Sodium alginate(1 to 6 %) and drug were dissolved in purified water 10 ml separately and 
mixed thoroughly with help of stirrer to form viscous dispersion. The resulting dispersion was 
added drop wise into 20% to 40% w/v calcium chloride solution  through a syringe with needle 
(size no 23) with continues stirring at 900 rpm. The added droplets were retained in the calcium 
chloride solution for 15 minutes to produce spherical rigid microspheres. The microspheres were 
collected by decantation, and the product thus separated was washed repeatedly with water and 
dried at 450C for 12 hours and stored in desiccators
2.Emulsion Solvent Evaporation90 ,44:
 
The drug and polymer in different proportions are weighed the polymer was co dissolved 
into previously cooled mixture of Ethanol : Dichloromethane at room temperature. The mixture 
was stir vigorously to form uniform drug polymer dispersion. The above organic phase was slowly 
added to100 ml of distilled water & 0.1 HCL containing 0.01% Span 80 by maintain the 
temperature at 20°C to 30 °C and emulsified by stirring at 1200 rpm for 30 min . The formed 
Microspheres were filtered & washed with water and sieved between 30-50 mesh size, and dried 
overnight for 40 °C.
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3.Emulsification  Ionic Gelation method30-31:
The Emulsification method was utilized for the preparation of microspheres followed by 
cross-linking with calcium chloride Core material, Calcium Dobesilate (250 mg) was dispersed in 
8% aqueous solution of sodium alginate (10 ml). The aqueous phase was emulsified in  Coconut 
oil, the ratio 1:10 containing 2% (v/v) Span 80 using a mechanical stirrer (Remi Motors, India) at 
400–1000 rpm for 60 min to it 5ml of 8% calcium chloride dissolved in a mixture of methanol and 
isopropyl alcohol (2:3) was added slowly to the emulsion and stirred to assure efficient cross-
linking. Microspheres were collected by filtration in vacuum, washed with isopropyl alcohol thrice 
and finally air-dried at room temperature. Various formulations of alginate microspheres were 
prepared using the variables.
Table No.8: FORMULATION OF MICROSPHERES IONIC GELLATION METHOD   
(F1-F16)
F1 F2 F3 F4 F5 F6 F7 F8
Drug 250mg 250mg 250mg 250mg 250mg 250mg 250mg 250mg
Water 10ml 10ml 10ml 10ml 10ml 10ml 10ml 10ml
Sodium
Alginate
1% 2% 3% 4% 5% 6% 2% 3%
Calcium
Chloride
20%w/v 20%w/v 20%w/v 20%w/v 20%w/v 20%w/v 30%w/v 30%w/v
F9 F10 F11 F12 F13 F14 F15 F16
Drug 250mg 250mg 250mg 250mg 250mg 250mg 250mg 250mg
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Water 10ml 10ml 10ml 10ml 10ml 10ml 10ml 10ml
Sodium
Alginate
4% 5% 6% 2% 3% 4% 5% 6%
Calcium
Chloride
30%w/v 30%w/v 30%w/v 40%w/v 40%w/v 40%w/v 40%w/v 40%w/v
FORMULATION OF MICROSPHERES EMULSIFICATION IONIC GELLATION 
METHOD BY USING COCONUT OIL:
Table No.9:
FORMULATION OF MICROSPHERES EMULSIFICATION IONIC GELLATION 
METHOD BY USING GROUND NUT OIL:
Table No.10:
Ingredients F18
Drug 1 g
Sodium Alginate 1 g
Ingredients F17
Drug 1g
Water 10ml
Sodium Alginate 8%
Span80 2%v/v
Methanol 2ml
Isopropyl Alcohol 3ml
Coconut oil 100ml
Calcium Chloride 6%w/v
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Hpmc k100 1 g
Water 50ml
Groundnut oil 300ml
FORMULATION OF MICROSPHERES EMULSION SOLVENT EVAPORATION 
METHOD (F19-F24):
Table No.11:
Ingredients F19 F20 F21 F22 F23 F24
Drug 1g 1g 1g 1g 1g 1g
Ethyle cellulose 2.250g 2.250g 1.500g 500mg 1g
Hpmc k100 750mg _ _ 750mg _ _
Eudragit   L100 _ 750mg 1.500g 2.250g _ _
Hpmc k4 _ _ _ _ 500mg 1g
Dichloro Methane 30ml 30ml 30ml 30ml 30ml 30ml
Ethanol 30ml 30ml 30ml 30ml 30ml 30ml
Water 100ml _ _ _ _ _
HCL 0.1N _ 100ml 100ml 100ml 100ml 100ml
Span 80 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
CHAPTETR 6                                                                                                     MATERIALS AND 
METHODS
 Dept. of Pharmaceutics,Annai Veilankanni’s Pharmacy College, Saidapet. Page 53
EVALUATION OF MICROSPHERES:
฀ Determination of percentage yield
฀ Drug entrapment efficiency 
฀ Particle size analysis
฀ In-vitro drug release
฀ In-vitro release kinetics
1.Determination of percentage yield: 
Microspheres dried at room temperature were weighed and the yield of microspheres was 
calculated using the formula.
Percentage yield   =  
Practical yield (gm)
 Theoretical yield
×  100
2.Drug entrapment efficiency:
The amount of drug entrapped was estimated by dissolving the 100mg of microspheres in 
ethanol and 6.8ph in 5:95 ratio ,under vigorous shaking for 1hr, the resultant solution is soaking 
with in 12 hrs,  and filtered to this 1ml was taken and dilueted with 10ml of 6.8 ph buffer ,. The 
drug content in  solution was analyzed by using UV at 302nm with further dilutions against 
appropriate blank. 
The amount of the drug entrapped in the microspheres was calculated using the formula:
Drug entrapment efficiency (%) =  
Amount of drug actually present 
Theoretical drug load expected
×  100
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3.Particle size analysis:
Determination of average particle size of Calcium Dobesilate microspheres with carrier 
was very important characteristic. It was measured by using optical microscope
4.In vitro dissolution studies 
The in vitro release of drug from the micro particles was carried out in basket type 
dissolution containing 900 ml of 6.8 pH phosphate buffer for 24 hrs. The volume of the dissolution 
media was maintained at 900 ml with constant stirring (50 rpm) and temperature of bath was 
maintained at 37 ± 0.5°C. Aliquots (10 ml) of dissolution media were sampled at specified time 
intervals and replaced with fresh media immediately after sampling. Samples were analyzed for 
drug content by UV visible spectroscopy (ELICO).The release data obtained were fitted into 
various mathematical models. Dissolution studies were carried out for all the batches of the 
prepared formulations 
i.e. F19,F20,F21,F22,F23,F24. (6 batches)  and compared.
Fig. No.11: VEEGO Dissolution Apparatus:-   
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Table No.12: Description of VEEGO Dissolution  Apparatus:- 
5.In-vitro release kinetics: 
To  analyze  the  In-vitro  release  data  various  kinetic  models  were  used  to describe the 
Medium 6.8 pH phosphate 
buffer
Volume 900 ml
RPM 50
Apparatus USP I basket type
Temperature 37.0 0c ± 0.50c 
Time intervals 2,4,8,12,16,20…24 hrs
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release kinetics. The zero order rate Equation describes the systems where the drug release rate 
is independent of its concentration.  The first order Equation describes the release from system 
where release rate is concentration dependent. 
Higuchi (1963) described the release of drugs from insoluble matrix as a square root of 
time dependent process based on Fickian diffusion.
The results of In-vitro release profile obtained for all the formulations were plotted in 
modes of data treatment as follows:
฀ Zero - order kinetic model – Cumulative % drug released versus time.
฀ First – order kinetic model – Log cumulative percent drug remaining versus time.
฀ Higuchi’s model – Cumulative percent drug released versus square root of time. 
฀ Korsmeyer equation / Peppa’s model – Log cumulative percent drug released versus log 
time.
1.Zero order kinetics:
Zero order release would be predicted by the following equation:
                                           At = A0 – K0t   
Where,
At = Drug release at time‘t’
A0 = Initial drug concentration.
K0 = Zero- order rate constant (hr-1)
      When the data is plotted as cumulative percent drug release versus time, if the plot is linear 
then the data obeys Zero – order kinetics and its slope is equal to Zero order release constant K0.
2.First order kinetics:
First - order release could be predicted by the following equation:
 Log C = log C0 – Kt / 2.303
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           Where,
            C = Amount of drug remained at time‘t’
            C0 = Initial amount of drug.
            K = First - order rate constant (hr-1).
   When the data plotted as log cumulative percent drug remaining versus time, 
yields  a  straight  line,  indicating  that  the  release  follow  first  order  kinetics.  The constant 
‘K1’ can be obtained by multiplying 2.303 with the slope value.
3.Higuchi’s model:
       Drug release from the matrix devices by diffusion has been described by following Higuchi’s 
classical diffusion equation:
 Q = [DЄ / τ (2A – ЄCs) Cst] 1/2
        Where,
        Q = Amount of drug release at time‘t’
                             D = Diffusion coefficient of the drug in the matrix. 
                             A = Total amount of drug in unit volume of matrix.
                             Cs = Solubility of drug in the matrix.
        Є = Porosity of the matrix. 
        τ = Tortuosity.
         t = Time (hrs at which q amount of drug is released.
Above equation can be simplified as if we assume that ‘D’, ‘Cs’ and ‘A’ are constant. Then 
equation becomes:
 Q = Kt1/2
When the data is splitted according to equation i.e cumulative drug release versus square 
root of time yields a staright line, indicating that the drug was released by diffusion mechanism.the 
slope is equal to ‘k’.ss
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4.Korsmeyer equation / Peppa’s model:
To study the mechanism of drug release from the liposomal solution, the release data was 
also fitted to the well-known exponential equation (Korsmeyer equation/ Peppa’s law equation), 
which is often used to describe the drug release behavior from polymeric systems.
 Mt / Mα = Ktn
Where,
Mt / Mα = the fraction of drug released at time‘t’.
K = Constant incorporating the structural and geometrical characteristics of the drug / 
polymer system.
n = Diffusion exponent related to the mechanism of the release.
 Above equation can be simplified as follows by applying log on both sides,
                               Log Mt / Mα = Log K+ n Log t
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7.RESULTS AND DISCUSSION
1.Preformulation studies:
Table No.13:- Identification of API
S.No PARAMETER STANDARAD VALUES OBSERVED VALUES
1. Appearance Colour:  white or almost white 
hygroscopic   powder
Odour:  none
Taste:     bitter
white or almost white 
hygroscopic   powder
Odour-none, 
Taste -bitter.
2. Texture Amorphous powder Amorphous powder 
3. Solubility Very soluble in water, freely 
soluble in anhydrous ethanol 
,very slight soluble in2-
propanol,practically insoluble in 
methylene chloride 
Very soluble in water, freely 
soluble in anhydrous ethanol 
,very slight soluble in2-
propanol,practically insoluble 
in methylene chloride.
4. Melting point 251°C. 2470c
5. % Purity 98% 97%
6. λ- max 221nm-355nm 302nm
Table No.14: The solubility of the calcium Dobesilate is shown following:
S.No Solubility Media Descriptive term
1 Water  Soluble 100mg in 1ml
2 Methanol Soluble 100mg in 3ml
3 Ethanol Soluble 100mg in 1ml
4 Ph 6.8 Buffer Soluble 100 mg in 10ml
CHAPTER 7                                                                                           RESULTS AND 
DISCUSSION
Dept. of Pharmaceutics, Annai Veilankanni’s Pharmacy College, Saidapet.  Page 59
2.Hausner,s ratio, Carr;s index: 
On analyzing for density it was found that calcium dobesilate showed bulk d e n s i t y    
value 0.91gm/cc  and  tapped  density  value 1.04 gm/cc, The value of Carr’s Index for 
16.5 and drugs showed good flow characteristics ,The value of Hausner’s ratio for 
calcium dobesilate was 1.14 drugs showed good flow characteristics
Table No.15:-Characterization of Micro Meritic parameters of Calcium 
Dobesilate pure drug:
S.No. Parameters Observations
2 Angle of repose 15.410
3 Bulk density 0.91gm/cc
4 True density 0.405gm/cc
5 Tapped density 1.04gm/cc
6 Compressibility  index% 14.28%
7 Cares index % 16.5%
8 Hausner‘s ratio 1.14
9 Drug content 98%
10 Melting point 2470 c
11 Particle size 14.28.µm
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3.STABILITY STUDIES:
FTIR Spectral studies:
Fig. No.12: FT-IR Reports for API of CALCIUM DOBESILATE:
Fig. No.13: FT-IR Reports for CALCIUM DOBESILATE with HPMCK100 
formulation: 
CHAPTER 7                                                                                           RESULTS AND 
DISCUSSION
Dept. of Pharmaceutics, Annai Veilankanni’s Pharmacy College, Saidapet.  Page 61
Fig. No.14: FT-IR Reports for CALCIUM DOBESILATE with Eudragit L100 formulation: 
Fig. No.15: FT-IR Reports for CALCIUM DOBESILATE with Ethyl cellulose 
formulation: 
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Fig. No.16: FT-IR Reports for CALCIUM DOBESILATE with Sodium alginate:
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4.Analytical method:
Table No.16: Calibration curve values for estimation Calcium Dobesilate in 
6.8 PH phosphate buffer: 
 
S.no Concentration
(μg/ml)
Absorbance
0 0 0
1 10 0.168
2 20 0.330
3 30 0.512
4 40 0.673
5 50 0.840
Fig. No.17:Standard calibration curve of Calcium Dobesilate in 6.8pH at 302nm:
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5.Evaluation of microspheres:
Percentage Yield, Entrapment Efficiency and Mean Particle size of Calcium Dobesilate 
microspheres:
 Table No.17: Percentage Yield, Entrapment Efficiency and Mean Particle size of 
Calcium Dobesilate microspheres from formulation F19 to F24:
Batch code
Percentage 
yield(%)
Entrapment 
efficiency
Rounded mean 
particle size (µm)
F19 28.52 20.71 25.7
F20 55.10 35.92 27.4
F21 80.11 73.15 29.3
F22 64.01 50.20 24.1
F23 20.02 3.2 18.2
F24 33.20 12.05 23.3
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Fig. No.18: Mean Particle size of Calcium Dobesilate microspheres from formulation 
F19 to F24:
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Fig. No.19: % of Yield, Entrapment efficasy of Calcium Dobesilate microspheres from 
formulation F19 to F24:
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6.In-vitro drug release studies
Table No.18: % drug release of Calcium Dobesilate Microspheres:
Time 
(hr)
F19 F20 F21 F22 F23 F24
0 0.00 0.00 0.00 0.00 0.00 0.00
1 7.1 9.7 10.9 9.4 18.3 16.7
2 11.4 10.9 15.4 12.5 29.3 27.4
3 16.3 15.1 20.2 16.1  34.4 35.1
4 19.3 19.1 24.1 20.1  40.9 45.3
6 22.3 29.2 33.2 28.4  58.2 53.1
8 25.4 37.3 41.9 42.8  78.2 65.3
10 33.1 49.3 49.2 50.7  90.5 76.2
12 39.7 62.4 55.4 59.4 96.2 86.1
14 47.2 71.3 70.4 71.7 _ 97.8
16 51.3 75.2 79.7 88.7 _ _
18 53.4 78.2 86.9 97.1 _ _
20 55.2 _ 91.1 _ _ _
22 59.3 _ 96.4 _ _ _
24 61.2 _ 98.2 _ _ _
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Fig. No.20: % OF DRUG RELEASE OF CALCIUM DOBESILATE:
Fig. No.21: % OF DRUG RELEASE OF CALCIUM DOBESILATE:
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Fig No.22: Percentage drug release of optimized formula F21:
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Fig. No.23: Zero order release of optimized formula F21:
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Fig.No.24:  Peppas mechanism of optimized formula F21:
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Fig. No.25:   1st Order of optimized formula F21:
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Fig. No.26:  Higguchi mechanism of optimized formula F21:
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Fig. No.27: COMPARISION OF % OF DRUG RELEASE OF CALCIUM DOBESILATE:
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               The present research work is an attempt made to  Formulation And Evaluation Of 
Calcium Dobesilate Microspheres for the treatment of Chronic Venous Disease by using Ionic 
Gelation and Emulsion Solvent Evaporation methods, Emulsification Ionic Gelation methods. 
For preparation of these methods by using different polymers like HPMC K100, Eudragit 
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L100, Ethyl Cellulose, Sodium Alginate, HPMC K4M were used. Based on the 
investigational reports we concluded the following results and discussions.
Preformulation Studies:
             The reports indicate the exhibit good and passable flow properties. So there is no 
need to improve the flow of the powder. The regression value obtained from analytical 
method development in buffer media is 0.999,  So, the drug is exhibiting linearity in 
concentration 10μg to 50 μg. The FT-IR spectral studies indicate good stability and no 
chemical interaction between the drugs and excipients used.
Identification of  Calcium Dobesilate:
            In identification of  API it was found  that Calcium Dobesilate  was soluble in   
Methanol, Ethanol, Water .
Solubility studies: 
Table No.19:Solubility of Calcium Dobesilate :
Calcium Dobesilate  is soluble in methanol, ethanol, water
Melting Point:
         It was also found Melting point of Calcium Dobesilate was 247 0c,
Density:
 On analyzing for density it was found that Calcium Dobesilate showed bulk density 
value 0.91gm/ml and tapped density value 1.04 gm/ml,
Carr’s Index:
S.NO Solubility media Descriptive term
1 Water  Soluble 100 mg per 1ml
2 Methanol Soluble 100mg per 3ml
3 Ethanol Soluble 100 mg per 1ml
4 ph 6.8 buffer Soluble100 mg per 10 ml
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The value of Carr’s Index for 16.5 and drugs showed good flow characteristics
Compressibility Index:
The value of Compressibility Index for was 14.28, and drugs showed good 
characteristics.
Hausner’s ratio:
The value of Hausner’s ratio for Calcium Dobesilate was 1.14 drugs showed good 
flow characteristics.
Angle of Repose:
The studies on angle of repose showed that   was 15.41 values   indicated good flow 
properties.
Stability studies:-
FTIR studies:
             From the FTIR spectra, it was concluded that similar characteristic peaks with minor 
difference for the drug and their formulation. Hence, it appears that there was no chemical 
interaction between the drugs and excipients used. The IR Spectra of Calcium Dobesilate 
with HPMC - K100, Eudragit Rs100, Ethyl cellulose, Sodium Alginate. The peaks were 
observed in as well as Calcium Dobesilate with excipients.
EVALUATION OF MICROSPHERES:
Determination of % yield: 
            The percentage yield was estimated from all the 18 formulations the results obtained 
between the range 80 % to   12  %.
Drug entrapment efficiency:
            The drug entrapment of all formulation of Calcium Dobesilate microspheres varied 
from 73% to 12% 
Particle size analysis:
             The particle size of the microspheres of the Calcium Dobesilate formulations varied 
from 18 µm  to 29 µm.
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In vitro drug release studies:
            The  formulation  F1 to F16 contains  Sodium Alginate is polymer (1 - 6%) & 
Calcium Chloride is cross linking agent (20 - 40%) are  prepared  by Ionic Gelation  method.    
Here we observed, the sphears are slowly dispersed in cross linking agent. May be the reason 
is Calcium- Calcium interaction & sodium alginate  is incompatible with drug. Here  very 
low yield value is observed. So dissolution studies were not conducted.
            The formulation  F17 containing 8% Sodium Alginate, Calcium Chloride containing 6 
%. This method is prepared by Emulsification Ionic Gelation Method. Here emulsifying 
agent is used as Coconut Oil. Here also Microspheres are formed  but low yield value is 
observed, So dissolution studies were not conducted.
The formulation F18 that containing 1g  of Sodium Alginate, Calcium Chloride 
containing 6 % & HPMC K100 1g. This method is prepared by Emulsification Ionic Gelation 
Method. Here emulsifying agent is used as  Ground nut Oil. Here also Microspheres are 
formed but very low yield because of  Calcium- Calcium interaction is there & clanging of 
oil. So dissolution studies were not conducted.
 The formulations  F19 - F24 are prepared by Emulsion Solvent Evaporation method. 
The F19 contains EC 2.250g & HPMC K100 750mg. The volatile organic solvents are DCM, 
Ethanol & water is used as medium. The yield value was 28% & the drug content is 20%. 
Here Microspheres are formed but low yield value was observed. 
 The F20 contains EC 2.250g & Eudragit 750mg. The volatile organic solvents are 
DCM, Ethanol & 0.1N HCL is used as medium. The yield value was 55% & the drug content 
is 35.9%. The dissolution studies are 78.2% at 18 hrs. This formula is not reached up to the 
mark. 
             The F22 contains HPMC K100 750mg & Eudragit 2.250g. The volatile organic 
solvents are DCM, Ethanol & 0.1N HCL is used as medium. The yield value is 64% & the 
drug content is 50.2%. The dissolution studies are 97.1% at 18 hrs. This formula is not 
reached up to the mark because the yield value is half of the total amount of the formula.
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 The F23 contains EC 500mg & HPMC K4M 500mg. The volatile organic solvents 
are DCM, Ethanol & 0.1N HCL is used as medium. The yield value is 20% & the drug 
content is 3.2%. Here the yield value is very low. This formula is failed to reached the object.
The F24 contains EC 1g & HPMC K4M 1g. The volatile organic solvents are DCM, 
Ethanol & 0.1N HCL is used as medium. The yield value is 33% & the drug content is 12%.  
This formula is not reached up to the mark because the yield value  low. It is also not fulfil 
the  object. 
The F21 contains EC 1.5g & Eudragit L100 1.5g. The volatile organic solvents are 
DCM, Ethanol & 0.1N HCL is used as medium. The yield value is 80% & the drug content is 
73%.  Here we got high yield value & drug entrapment efficasy also increased. The 
dissolution studies are 98.2% at 24 hrs  This formula is reached up to the mark . It is fulfil the 
object. 
Finally among all the formulations F21 is full fill the object.
 Effect of method of preparation
฀ Ionic Gelation
฀ Solvent evaporation
1. On particle size :
From formulations F1to F16 are by Ionic Gelation method.
From formulations F17-F18 are by Emulsification Ionic Gelation method.
From
 F1-F18 - low yield value & highly swelling observed because of drug is incompatible with 
Sodium Alginate & calcium - calcium interactions. 
 formulations F19 to F24 are by Emulsion Solvent Evaporation method, are in desired 
particle size range i.e is 18μm - 29 μm. 
 So that Spheres obtained are smaller than  by Ionic Gelation method.
2. On Drug release:
Drug release is controlled in formulations prepared by Emulsion  solvent evaporation than 
Ionic Gelation method  and emulsification ionic Gellation method
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Therefore finally Emulsion  Solvent Evaporation Method is selected to fulfil the object.
Effect of polymers
 HPMC K100, Ethyl Cellulose, Eudragit L100, Sodium Alginate are 4 different polymers 
used as controlled release polymers.
Formulations F1 - F17 are prepared by Orifice Ionic Gelation method with single polymer  
that is Sodium Alginate, where as F18 is prepared by  Emulsification Ionic Gelation method  
with dual polymers they are Sodium Alginate, HPMC K100 respectively.
Remaining all formulations F19 - F24 are combination of two each polymers of respective 
ratios.
HPMC K100 is hydrophilic, Ethyl cellulose is hydrophobic nature. Combination of 
Hydrophilic and Hydrophobic polymers is tested at different ratios  to determine effect on 
controlled drug release.
Also HPMC K100 with coating polymer Eudragit L100 combination is tested at different  
ratios.
Among all these ,F21 i.e, with  Eudragit L100, Ethyl Cellulose by solvent evaporation 
method shows desired drug release compared to all other formulations.
Therefore it is concluded that there is an effect of combination of polymers(Eudragit L100, 
Ethyl Cellulose) on  controlled drug release of Calcium Dobesilate microspheres.
Kinetics of drug release from optimized formulation
The kinetics of the drug release was evaluated by drug release rate models namely zero order, 
First order. The mechanisms of drug release was evaluated by Zero order drug release & 
followed Pappas mechanism.
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8.SUMMARY AND CONCLUSION
The present investigations were  Formulation And Evaluation Of Calcium 
Dobesilate Microspheres for the Treatment of Chronic Venous Disease was developed to 
prolong action.
The summary and conclusions of investigations is as follows
1. The present study was carried out to design the controlled release microspheres  for 
the Calcium Dobesilate for  treatment of Chronic Venous Disease.
2. The microspheres were formulated for controlled release by using different polymers 
like HPMC K100, Eudragit L100, Ethyl Cellulose in different ratios  was found to 
control and stable drug release.
3.  Sodium Alginate & Calcium Chloride is prepared  by Ionic Gelation  method. Here 
Calcium- Calcium interacted & sodium alginate  is incompatible with drug. So 
spheres are not formed.
4. The use of Ethyl Cellulose and Eudragit L100  polymer makes  a controlled  release 
of  Calcium Dobesilate microspheres with dissolution mechanism.
5. By using the enteric polymer Eudragit L100, increases the drug entrapment efficasy & 
yield value in 0.1N HCL than water. The reason is Eudragit L100 is insoluble in 0.1 n 
HCL.
6. These concept is explained the application of fixed dose dosage form which results in 
cost –effectiveness and reduce multiple of dosage forms.
7. From the above observations it is concluded that by Emulsion Solvent Evaporation 
Technique Formulation F21 was found 98.2 % at 24 hrs drug release
8. The release characteristics of the formulation appear as to follow F21 shows near zero 
order drug release and Zero order- Pappas mechanism.
9. Among all the techniques the best method was found Emulsion Solvent Evaporation  
method for Calcium Dobesilate.  
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